We report a rare case of an early, severe dermatological adverse event (dAE) to two AIs in a pre-menopausal patient receiving adjuvant treatment for human epidermal growth factor receptor 2 negative (HER2-) HR+BC. The gene discussed is ERBB2; the disease is breast cancer.